Abstract
Women with the BRCA1/2 mutations, which cause hereditary breast and ovarian cancer (HBOC), are 35–40 times more likely to develop ovarian cancer compared with the general population. We treated a patient in whom ovarian carcinosarcoma was identified during surveillance for HBOC. She had suffered from breast cancer at ages 45 and 50. At the age of 54 years, she was diagnosed as carrying an “uncertain significant” BRCA1 variant using a genetic mutation analysis. She was referred to our department, and surveillance was performed every 3–6 months for BRCA1 pathogenic mutation carriers due to her family history. At the age of 62 years, cervical and endometrial cytology suggested a diagnosis of adenocarcinoma. At this point, the CA125 level was 19.7 and positron emission tomography/computed tomography (PET/CT) images revealed a right ovarian tumor (SUVmax, 7.41). Surgery was performed, and ovarian carcinosarcoma (pT3cN0M0) was diagnosed. Adjuvant chemotherapy consisting of paclitaxel and carboplatin was initiated. In the month during which the cancer was identified, BRCA1 variant mutation was re-designated as “suspected deleterious,” and 8 years after the initial genetic diagnosis, the causative mutation was identified. The patient has been disease-free for 4 years since surgery. This case demonstrates both the importance and difficulty of surveillance.
References
(2009) The general rules for clinical and pathological management of ovarian tumors; part 1: histological classification and color atlas of ovarian tumors. Jpn Soc Pathol 19–20
Harris MA, Delap LM, Sengupta PS et al (2003) Carcinosarcoma of the ovary. Br J Cancer 88:654–657
Silasi DA, Illuzzi JI, Kelly MG et al (2008) Carcinosarcoma of the ovary. Int J Gynecol Cancer 18:22–29
Chun KC, Kim JJ, Kim DY et al (2011) Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcoma: a single center experience. Gynecol Obstet Invest 2011:208–214
Sonoda Y, Saigo PE, Federici MG et al (2000) Carcinosarcoma of the ovary in a patient with a germline BRCA2 mutation: evidence for monoclonal origin. Gynecol Oncol 76:226–229
Bast RC Jr, Mills GB (2010) Personalizing therapy for ovarian cancer: BRCAness and beyond. JCO 28:3545–3548
Miki Y, Swensen J, Shattuck-Eidens D et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71
Wooster R, Bignell G, Lancaster J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792
Ford D, Easton DF, Stratton M et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676–689
Bolton KL, Chenevix-Trench G, Goh C et al (2012) Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA 307:382–390
Yang D, Khan S, Sun Y et al (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306:1557–1565
Gómez García EB, Oosterwijk JC, Timmermans M et al (2009) A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res 11:R8
Finch A, Beiner M, Lubinski J et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with BRCA1 or BRCA2 mutation. JAMA 296:185–192
Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975
(2013) National Cancer Network: NCCN Clinical Practice Guidelines in Oncology Genetic/Familial High-risk Assessment: Breast and Ovarian
Van der Velde NM, Mourits MJ, Arts HJ et al (2009) Time to stop ovarian screening in BRCA1/2 mutation carriers? Int J Cancer 124:919–923
Arai A, Taki K, Iwase H et al (2012) Present status and tasks for genetic testing and risk-reducing surgery in patients with hereditary breast and ovarian cancer (in Japanese). Gan to kagaku ryoho 39:525–531
Takeshima N, Teshima H, Minami T et al (1994) The clinical usefulness of the endometrial cytology using Masubuchi’s aspiration tubes in ovarian and fallopian tube cancer (in Japanese). J Jpn Soc Clin Cytol 33:1086–1091
Acknowledgments
We are grateful to Ms. Ashihara and Ms. Kita Department of Clinical Genetic Oncology, for their constant encouragement and support. We also appreciate the pathological review provided by Dr. Motoyama.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Abe, A., Sakamoto, K., Taniguchi, T. et al. The presentation of an asymptomatic ovarian carcinosarcoma caught by BRCA1 mutation surveillance program. Int Canc Conf J 3, 242–246 (2014). https://doi.org/10.1007/s13691-014-0155-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-014-0155-9